STEPS
New Drug Reviews

Gepotidacin (Blujepa) for the Treatment of Uncomplicated UTIs in Female Patients

Gregory Castelli, PharmD
Angelique Lynch-Jiles, MD, MPH

American Family Physician. 2026;114(5):542-543.

Author Disclosure: No relevant financial relationships.

Drug Dosage Dose form Cost*
Gepotidacin (Blujepa) 1,500 mg twice daily for 5 days 750-mg tablet $1,900 for 20 750-mg tablets

*—Estimated retail price of one course of treatment. Actual cost will vary with insurance and by region. Information obtained at https://www.goodrx.com​ (accessed September 2, 2026; zip code: 66211).

Gepotidacin (Blujepa) is a bactericidal antibiotic labeled for the treatment of uncomplicated urinary tract infections (UTIs) in female patients 12 years and older weighing at least 40 kg (88 lb). Its mechanism of action to inhibit DNA replication is slightly different from the fluoroquinolone drug class. Gepotidacin is also labeled for the treatment of uncomplicated urogenital gonorrhea in male and female patients 12 years and older.

SAFETY

The main safety concern with gepotidacin is QTc prolongation with a theoretical risk of arrhythmia induction. It should not be used in patients with a history of QTc prolongation, with relevant cardiac disease, or who are taking other medications that prolong the QTc interval. Strong cytochrome P450 3A4 inhibitors (eg, itraconazole, clarithromycin, grapefruit juice), severe renal impairment (estimated glomerular filtration rate less than 30 mL/min/1.73 m2), and severe hepatic impairment (Child-Pugh class C) raise gepotidacin serum levels and may increase QTc prolongation risk.1

Gepotidacin reversibly inhibits acetylcholinesterase.1 Patients taking neuromuscular blocking agents or anticholinergic medications should be monitored while being treated with gepotidacin. Dysarthria, syncope, and muscle spasms have been reported in clinical trials.1Clostridioides difficile infection may occur (in less than 1% of patients) and requires evaluation if diarrhea develops. No data are available on the use of gepotidacin in pregnant patients to evaluate for risks of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. No data are available on the presence of gepotidacin in breastmilk or its effects on breastfeeding infants.

TOLERABILITY

The most common adverse effects are diarrhea (14% to 18%), nausea (8% to 11%), and abdominal pain (4%). In premarketing studies, 3% to 6% of patients discontinued treatment with gepotidacin due to adverse effects, compared with 2% of patients taking nitrofurantoin.1

EFFECTIVENESS

Gepotidacin was studied in two randomized trials that enrolled 3,136 female patients 12 years and older who weighed at least 40 kg with uncomplicated UTIs due to Escherichia coli, Klebsiella pneumoniae, Citrobacter freundii complex, Staphylococcus saprophyticus, or Enterococcus faecalis.2,3 A 5-day course of gepotidacin was similar to nitrofurantoin for complete symptom resolution and microbiological eradication between days 10 and 13 (50.6% vs 47% in trial 1 and 58.5% vs 46% in trial 2). In the second trial, a similar proportion of participants required treatment with a second antibiotic due to lack of symptom resolution. Studies to determine if treatment with gepotidacin is a viable option for pregnant patients and female patients younger than 12 years would be useful given the limited treatment options available for these populations.

Gepotidacin has not been compared with other commonly used antibiotics such as trimethoprim, trimethoprim/sulfamethoxazole, or fosfomycin. Effectiveness for treating multidrug-resistant uropathogens or pyelonephritis is unknown. In a recent study, gepotidacin was shown to be comparable with ceftriaxone plus azithromycin in treating uncomplicated urogenital gonorrhea.4 In this study, neither regimen met the World Health Organization criterion of 95% effectiveness for treatment of gonorrhea (92.6% vs 91.2% microbiological success). Current available safety data for treatment of gonorrhea may be different than UTI treatment because the participants in this study were mostly men and medications were given at higher doses.

GREGORY CASTELLI, PharmD, is an associate professor at the University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

ANGELIQUE LYNCH-JILES, MD, MPH, is core faculty at the Tufts University Family Medicine Residency Program at Cambridge Health Alliance, Malden, Massachusetts.

Address correspondence to Gregory Castelli, PharmD, at castellig@upmc.edu.

Author Disclosure: No relevant financial relationships.

  1. 1.Daily Med. Drug label information. Blujepa—gepotidacin tablet, film coated. Accessed March 17, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=80b57cfe-7819-4d95-a57d-014af42f118d​
  2. 2.Perry C, Hossain M, Powell M, et al. Design of two phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants. Infect Dis Ther. 2022;11(6):2297-2310.
  3. 3.Wagenlehner F, Perry CR, Hooton TM, et al. Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials. Lancet. 2024;403(10428):741-755.
  4. 4.Ross J, Wilson J, Workowski K, et al. Oral gepotidacin for the treatment of uncomplicated urogenital gonorrhoea (EAGLE-1): a phase 3 randomised, open-label, non-inferiority, multicentre study. The Lancet. 2025;405:1608-1620.
  5. 5.Goodrx. Nitrofurantoin. Accessed September 2, 2026. https://www.goodrx.com

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in AFP is available at https://www.aafp.org/afp/steps.

Copyright © 2026 by the American Academy of Family Physicians.

This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. See permissions for copyright questions and/or permission requests.